What Exicure, Inc. does.

Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. In February 2024, we received an upfront payment of $500,000 from a licensing agreement for patents related to one of our historical drug candidates, and received a small, one-time payment and an entitlement to only modest royalties on future sales of the licensed technology that we do not believe will be material. In the second quarter of 2024, we recognized other income of $637,000 from the sale of our samples related to the licensed product. In the third quarter of 2024, we sold our historical biotechnology intellectual property and other assets (including the licensing agreement described above) pursuant to the purchase agreement and recognized other income of $1,500,000. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization.

Revenue and profit, by fiscal year.

More on XCUR.

• Exicure, Inc. summary
• Exicure, Inc. financial statements
• Exicure, Inc. key metrics
• Exicure, Inc. health scores and style box
• Exicure, Inc. earnings
• Exicure, Inc. dividends
• Exicure, Inc. valuation
• Exicure, Inc. ownership and insiders
• Exicure, Inc. peers

Figures from Exicure, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.